Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 261Gynecologic 6Tumor-Agnostic 4Thoracic 4Other solid neoplasm 4Breast 3Dermatologic 2NET 1Head & Neck 1Genitourinary 1Endocrine 1CNS 1

Conditions

Neoplasms 3Neoplasm Metastasis 2Adenocarcinoma 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Blood Specimen Collection 28Radiosurgery 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Folfox protocol × Tumor-Agnostic × Clear all
NCT04729205 2023-09-14

Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Folfox in Patients With GI Malignancies

Lipomedix Pharmaceuticals Inc.

Phase 1 Terminated
9 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT04167007 2020-08-18

GEMFOX

Assistance Publique - Hôpitaux de Paris

Phase 3 Unknown
400 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02195180 2018-07-27

Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma

ERYtech Pharma

Phase 2 Completed
141 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT00479583 2011-11-30

Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX

Bristol-Myers Squibb

Phase 1 Completed
25 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡